Millions of patients across the United States have had their lives upheaved by an unexpected diagnosis. While innovative treatment options have continued to expand over the years, not all patients are able to access these medications or even determine what treatment is right for them.
Biomarker testing can help patients learn important details about their condition and identify the best treatment plan more quickly and accurately, leading to improved survivorship and better quality of life. Biomarker testing is increasingly important for cancer care and for the treatment of chronic and debilitating conditions, including diabetes, cardiovascular conditions, neurological disorders, and more.
Unfortunately, many patients are unable to access biomarker testing due to high out-of-pocket costs or lack of appropriate insurance coverage. Without increased access to biomarker testing, some populations may benefit more from these innovations than others, further increasing existing disparities in health outcomes for marginalized populations.
Help increase access to effective care for patients and promote health equity in North Carolina today.
Join us today and send a letter to your state lawmakers urging them to support House Bill 567, which will expand access to critical biomarker testing for patients across North Carolina and ensure patients can access the treatment that is right for them.
Dear [LEGISLATOR NAME],
As your constituent, I urge you to support House Bill 567, legislation that would expand access to biomarker testing and improve patient lives.
Biomarking testing allows doctors to learn more about a patient's specific disease, particularly for cancer care and for the treatment of chronic and debilitating conditions, including diabetes, cardiovascular conditions, neurological disorders, and more.
Biomarker testing can not only save lives and improve a patient's quality of life, but also potentially reduce health care costs by identifying the most effective treatment option for an individual patient. By avoiding treatments that might be ineffective or lead to negative side effects, patients can avoid unnecessary suffering and expedite their path to remission.
Unfortunately, insurance coverage for biomarker testing is failing to keep pace with innovations and advancements in treatment. Many patients are unable to access biomarker testing due to high out-of-pocket costs or lack of appropriate insurance coverage. Marginalized communities – including communities of color, with lower socioeconomic status, and in rural areas – are further burdened by existing barriers to care, and even less likely to receive biomarker testing.
I urge you to support House Bill 567 to improve access to biomarker testing for North Carolina patients.
Thank you,
[your name]
